Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2016 Financial Results

Seattle Genetics | February 09, 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2016 financial results on Thursday, February 9, after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update


Department of Genetics & Plant Biotechnology. This video about the biotechnology.

Other News

Medolife Rx Announces Changes to Management and Improvements to AELIA’s Marketing Efforts

Medolife Rx, Inc. | February 07, 2022

Medolife Rx, Inc. a global integrated biopharmaceutical company with manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s polarized ingredients. Medolife believes these changes will bring greater product awareness and improved online presence. The Company’s manager of marketing and brand development, Maggie Dumais, has stepped down from their position under mutual agreement with the Company. In order to support the Company’s vision of a new marketing strategy, Medolife is finalizing an agreement with a new director of marketing and brand development, whose name will be announced at a later date. “We are excited with the new direction that the Company is taking with its AELIA products and expect a positive outcomeThe Company’s values, goals and plans will be presented in a way that reflects our mission to promote health and well-being with our expanding line of products.” Medolife CEO Dr The Company also hired a new team to oversee the overhaul of AELIA’s websites, product listings and social media presence. The Company hopes that, with the help of these experienced professionals, their online platforms will see an increase in sale conversions and consumer feedback. Medolife thanks its shareholders and clients for believing in them. The Company will have more positive news coming out soon. About Medolife Rx Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian, who pioneered the unlaying polarization technology, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company intends to pursue product registration and drug approval in multiple countries. Through its subsidiary AELIA, Medolife manufactures and distributes consumer wellness products in consumer areas such as pain relief, beauty, and general wellness. AELIA products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption. Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife could have the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.

Read More


HistoSonics Announces Agreement with GE Healthcare

HistoSonics | May 24, 2022

HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare's LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of HistoSonics' novel sonic beam therapy. As part of the agreement and upon market authorization, HistoSonics will distribute GE Healthcare's LOGIQ E10 Series on a one-to-one basis with its breakthrough liver therapy system. HistoSonics' Edison™ system, currently in development, uses the novel science of histotripsy to non-invasively destroy targeted liver tissue. HistoSonics intends to utilize GE Healthcare's LOGIQ E10 Series, currently the most technologically advanced ultrasound platform for guiding radiology interventions, to provide treating physicians with continuous visualization for key and unique elements of the histotripsy therapy procedure, including planning, monitoring, and immediate post-treatment verification. This agreement is aimed to support HistoSonics' efforts to launch their EdisonTM system leveraging their deep domain expertise along with GE Healthcare's world-class ultrasound imaging technologies, digital infrastructure, data analytics and clinical decision support capabilities. We are very excited to formalize our imaging partnership with GE Healthcare, which is a key part of bringing our transformative therapy platform, and an entirely new treatment option, to the clinic and to patients, We've developed a very collaborative relationship with GE Healthcare and look forward to expanding our efforts to realize the full potential of histotripsy across clinical applications, specialties, and care settings." Josh Stopek, HistoSonics Vice President of R&D. HistoSonics' non-invasive platform combines advanced imaging and proprietary software to deliver patient specific treatments using histotripsy to mechanically destroy and liquify targeted tissues at a sub-cellular level. The company believes the novel mechanism of action of their proprietary technology may offer significant advantages to patients, including precise and predictable treatment zones with equivalent treatment effect throughout the entire treated volume. Early clinical and pre-clinical results also suggest that histotripsy largely preserves critical structures such as the liver capsule, and larger vessels and bile ducts within or adjacent to the treated volume of tissue. Additionally, histotripsy enables the treating physicians to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today. The agreement between GE Healthcare and HistoSonics comes as HistoSonics continues enrollment in their U.S. and European #HOPE4LIVER Trials, evaluating the safety and efficacy of histotripsy for the destruction of targeted primary or metastatic liver tumors. Additionally, the company recently was awarded "Breakthrough Device Designation" by the FDA for histotripsy of liver tissue, validating the company's vision that histotripsy has the potential to provide advantages over existing therapies such as surgery, radiation therapy and thermal ablation. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on the continued development of its EdisonTM Platform, global clinical studies, and new strategic projects including future clinical applications and platforms. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN.

Read More


RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies

RQ Bio | May 17, 2022

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio's existing mAbs against SARS-CoV-2. The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging and new viral infections. To maximise and accelerate patient impact, the company will continue to be supported by its collaborations with its scientific co-founders, the University of Oxford and leading UK medical research charity LifeArc. Professor Gavin Screaton, Head of the Medical Sciences Division at the University of Oxford, will continue to advise in his capacity as scientific and medical co-founder, as will Clare Terlouw, Head of LifeArc Ventures and UK BIA board member, as a member of the Board of Directors. Our vision is to build on our successful debut with neutralising antibody therapy for SARS-CoV-2 and develop innovative medicines to address current and evolving unmet needs in other viral infectious diseases, By combining our expertise and innovative excellence in core areas we have created a smarter approach to antibody generation making us uniquely positioned to deliver fast patient impact." Hugo Fry, CEO of RQ Bio. LifeArc is committed to backing leading UK academics and scientists, and we were inspired to fund RQ Bio because of the exceptional group of founders who are so passionately dedicated to finding new treatments and preventative therapies in areas of high unmet patient need, LifeArc provided support from across the Charity, including the venture team, scientific labs and other in-house experts to help RQ Bio execute on its business plan, and we look forward to further supporting RQ Bio as it becomes a world-leading infectious disease company." Clare Terlouw, Head of LifeArc Ventures. About RQ Bio RQ Bio's mission has been to develop medicines based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from current and future variants of viral infections. RQ Bio has achieved this by combining innovative excellence in core areas to create a smarter approach to antibody generation. RQ Bio has multiple sources of leads and a deep collaboration with the University of Oxford. RQ Bio was founded by scientific experts previously involved with the UK BIA Antibody Taskforce, which worked to build a community of infectious disease antibody experts focussed on the development of rapid and efficient delivery of highly potent neutralising antibodies to help support the UK COVID-19 response. About AstraZeneca Licensing Deal Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive worldwide licence to develop, manufacture and commercialise RQ Bio's exisiting early stage mAbs against SARS-CoV-2 and a right of first refusal to take an exclusive licence in respect of any additional mAbs against SARS-CoV-2. RQ Bio will receive upfront and milestone payments of up to $157 million and will be eligible to receive single digit royalties on sales. The successful licensing deal was supported by Oxford University Innovation (OUI), a wholly-owned subsidiary of the University of Oxford that manages the University's technology transfer and consulting activities, who worked efficiently and creatively with all parties on the corresponding technology licences and the filing of intellectual properties.

Read More


Relevate Health Acquires ConneXion360

Relevate Health | April 26, 2022

Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems. The addition of ConneXion360 expands the Relevate Health suite of HCP engagement marketing solutions for its clients with precision messaging at the point-of-care and point-of-prescribing and Key Account Messaging for 1:1 engagement, complemented by ConneXion360's National Broadcast capabilities and OnDemand platform for "non-personal" engagement. The combination enables Relevate Health's clients to gain access to difficult-to-reach health systems and HCPs via ConneXion360's industry-leading Treatment Perspectives Recruitment Network. These proven solutions will be integrated into Relevate Health's proprietary ElevatedRelevance℠ data platform to cultivate unique and actionable content, market selection, and Key Opinion Leader identification insights for its clients. Relevate Health's comprehensive suite of data-driven HCP Engagement solutions solves the last-mile challenge that many brands face in connecting their creative campaign to target HCP audiences. Relevate Health's digital activation services and marketing solutions plug into existing omnichannel infrastructure and spans the gamut from 1:1 to mass engagement. Bringing ConneXion360's 1:1 engagement, Key Account Messaging, immersive video, and national broadcast capabilities into the Relevate Health suite of products and technology offer new brand-building opportunities for our clients, Quite simply, it means more access to HCPs by the Reps, MSLs, and KAMs, richer opportunities to scale nationally using local data, and deeper omnichannel engagement. For clients seeking a digital-first omnichannel agency, we complement our highly differentiated engagement solutions with class-leading agency services, and digital activation capabilities that help our clients achieve their ambitious growth objectives." Relevate Health CEO Jeff Spanbauer. Relevate Health delivers innovative, integrated HCP omnichannel engagement solutions that are configured to meet clients' specific market challenges. Its unmatched capabilities in "non-personal" promotion, immersive video, peer-to-peer engagement, field rep access, and field rep enablement make Relevate Health the premier marketing partner. Relevate Health delivers precision, segmented, and scalable engagement solutions that overcome the increasing HCP access hurdles. Relevate Health is known for its use of data and machine learning to create locally relevant messages that are scalable, By adding ConneXion360's Treatment Perspectives Recruitment Network and our portfolio of proprietary Treatment Perspectives National & Local HCP Message Engagement Solutions, we can engage target HCPs with more precision, personalization, and relevancy at both national & local levels. Our clients now have access to a single premier partner with a full suite of product-driven, data-based solutions that deliver proven brand growth and extraordinary ROI among previously hard-to-engage HCP audiences." George Griffith, Co-Founder & CEO of ConneXion360. The acquisition of ConneXion360 marks the third transaction by Relevate Health since taking on funding from Denver-based private equity firm Mountaingate Capital in late 2020. Relevate Health's comprehensive system of marketing solutions enables clients of all sizes to deploy a platform that fits their needs. With this acquisition, Relevate Health becomes a single omnichannel partner that addresses the full range of HCP engagement challenges, from 1:1 to National Broadcast, providing field personal as well as brand, digital, and medical leaders with solutions that change HCP's behavior and deliver benchmark beating ROI. Relevate Health, founded in 2007, is an award-winning healthcare marketing agency for pharmaceutical, biotech, and medical device brands, recognized by MM&M, PM360, MedAdNews, and more. ConneXion360 is the leading Health System and HCP Recruitment Network that specializes in creating access for its clients to Health Care Professionals through its proprietary Treatment Perspectives Recruitment Network, National Broadcast platforms, and precision messaging at the point-of-care and the point-of-prescribing.

Read More